46th week of 2010 patent applcation highlights part 47 |
Patent application number | Title | Published |
20100292284 | Talarazole metabolites - Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO | 2010-11-18 |
20100292285 | METHOXYACRYLATE-BASED FUNGICIDE AND METHODS FOR PREPARING AND USING THE SAME - A pharmaceutical composition of fungicide including at least a compound represented by Formula (I). | 2010-11-18 |
20100292286 | Crystalline imidazole-5-carboxylic acid derivative - The invention provides the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl) 1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy] methyl ester), its preparation method and uses thereof. | 2010-11-18 |
20100292287 | Periodontitis treatment - The periodontitis treatment is a method for the prevention and treatment of periodontitis in mammals, including humans and dogs. The mammal may be diabetic or non-diabetic. the method includes the step of administering an effective amount of an aldose reductase inhibitor (ARI). The ARI may be (i) a phenolic derivative, such as quercetin, quercitrin (a 3-oxy-glucose analog of quercetin), rutin, and other polyphenols or bioflavonoids exhibiting an ARI effect; (ii) an acetic acid derivative, such as tolrestat, ponalrestat, etc.; (iii) a cyclic imide (or hydantoin), such as sorbinil, 2-methyl sorbinil, imirestat, etc.; and (iv) one of the phenylsulfonyinitromethtane derivatives, such as ZD-5522. In particular embodiments, the method may include, e.g., administering a diet containing about 0.08% quercetin (about 80 mg/kg/day), about 0.0125% imirestat (about 12 mg/kg/day), or about 0.015% tolrestat (about 20 mg/kg/day). | 2010-11-18 |
20100292288 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO - The present invention is directed to novel salts of (R)-1-{2-[4′-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and crystalline forms, and compositions thereof that modulate the activity of the histamine H3-receptor and are useful in the treatment of histamine H3-receptor associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, pain, dementia, Alzheimer's disease and the like. | 2010-11-18 |
20100292289 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES - The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention. | 2010-11-18 |
20100292290 | NOVEL PROCESS TO PREPARE ALMOTRIPTAN - The present invention relates to a novel process for the preparation of almotriptan and pharmaceutically acceptable salts thereof, which affords product conveniently and efficiently with commercially acceptable yields and purity. The present invention also relates to a novel synthetic intermediate used in the process. | 2010-11-18 |
20100292291 | FORMULATIONS OF DEACETYLASE INHIBITORS - The present invention provides a stable parenteral formulation of histone deacetylase inhibitors. | 2010-11-18 |
20100292292 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs - Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits the aggregation of α-synuclein. | 2010-11-18 |
20100292293 | THERAPEUTIC SUBSTITUTED LACTAMS - Disclosed herein are compounds having a formula: (I) Compositions, methods, and medicaments related thereto are also disclosed. | 2010-11-18 |
20100292294 | Compositions Comprising a Physiological Coolant - The present invention concerns enhancements in the cooling effects of certain physiological coolant-containing compositions such as topically applied cosmetic, toiletry or pharmaceutical products, wherein the cooling effect of the physiological coolants is enhanced by the addition of a substance according to formula (I) or dermatologically acceptable salts thereof: | 2010-11-18 |
20100292295 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS - The present invention provides a compound of Formula (IA) or a pharmaceutically acceptable salt thereof:
| 2010-11-18 |
20100292296 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 2010-11-18 |
20100292297 | Micrornas That Regulate Muscle Cell Proliferation and Differentiation - The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter. | 2010-11-18 |
20100292298 | METHOD AND REAGENTS FOR TREATING HEPATIC FIBROSIS AND INFLAMMATION - The invention relates to methods for identifying an anti-fibrotic or anti-inflammatory agent comprising determining cathepsin S expression in activated hepatic stellate cells which have been exposed to a test compound and comparing expression to non-exposed hepatic stellate cells. The invention also relates to methods for treating a disorder characterised or caused by hepatic fibrosis or inflammation, comprising administering a cathepsin S inhibitor to a subject. | 2010-11-18 |
20100292299 | Nucleotide Motifs Providing Localization Elements and Methods of Use - The instant invention describes nucleotide motifs comprising a localization element and small RNA molecules comprising the localization motifs, and methods of use in gene silencing. The nucleotide motifs have use in preventing and treating diseases or disorders. | 2010-11-18 |
20100292300 | COMPOSITIONS AND METHODS FOR INHIBITING OR REVERSING FIBROTIC DISORDERS - The present invention provides compositions and methods for inhibiting or reversing fibrotic disorders by administering a Hic-5 antagonist to a mammal in need thereof. The invention also includes methods for screening compounds to identify Hic-5 antagonists useful in inhibiting or reversing fibrotic disorders. | 2010-11-18 |
20100292301 | NOVEL SIRNA STRUCTURES - The present invention provides novel compounds, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of a target gene. More specifically, the present invention relates to positional motifs of modified ribonucleotides useful in the design of siRNA compounds. In particular, the ribonucleotides include modified internucleotide linkages and/or modified sugar moieties. These novel siRNA compounds may be used therapeutically to treat a variety of diseases and indications. | 2010-11-18 |
20100292302 | INDUCTION OF APOPTOSIS AND INHIBITION OF CELL PROLIFERATION THROUGH MODULATION OF CARNITINE PALMITOYLTRANSFERASE 1C ACTIVITY - This invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for treating tumors by inhibiting the activity of CPT1C. The methods and compositions can additionally include inhibition of glycolysis. | 2010-11-18 |
20100292303 | GENE EXPRESSION PROFILE FOR PREDICTING OVARIAN CANCER PATIENT SURVIVAL - A gene profiling signature for predicting ovarian cancer patient survival is disclosed herein. The gene signature can be used to diagnosis or prognosis ovarian cancer, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for diagnosing and prognosing an ovarian tumor, such as ovarian cancer, in a subject. Methods are also provided for identifying agents that can be used to treat an ovarian tumor, for determining the effectiveness of an ovarian tumor treatment, or to predict the metastatic potential of an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian survival factor-associated molecules and ovarian tumor in the subject. | 2010-11-18 |
20100292304 | COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS - The present invention provides method of optimizing the efficacy and potency of antisense drugs. In certain embodiments, the invention provides assays useful for determining favorable oligonucleotide characteristics and excipeints for improved cellular uptake. | 2010-11-18 |
20100292305 | RNAi MODULATION OF HIF-1 AND THERAPUTIC USES THEREOF - The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified. | 2010-11-18 |
20100292306 | Compositions And Methods For The Treatment Of Muscular Dystrophy - Compositions and methods for treatment of individuals diagnosed with a dystrophin deficiency are disclosed. In particular, inhibitors of NFκB transactivation and/or inhibitors that suppress p65 expression are used to prevent and/or reverse muscle damage in animals or humans lacking dystrophin. Such compositions and methods are useful in the treatment of individuals with muscular dystrophy. | 2010-11-18 |
20100292307 | Construct - A promoter for high level and sustained expression is provided which can be used for gene expression of chosen sequences in general. In particular, a nucleic acid construct comprising a hCEF1 promoter operably linked to a sequence for expression is provided, where the hCEF1 promoter comprises: (i) a human CMV enhancer operably linked to a human EF1 a promoter; (ii) a functional fragment of (i); or (ii) a functional variant of (i) or (ii). | 2010-11-18 |
20100292308 | MICRORNA MOLECULES | 2010-11-18 |
20100292309 | INDUCING IMMUNE-MEDIATED TUMOR CELL DEATH - This document provides methods and materials related to treating cancer. For example, methods and materials that include using CD40L polypeptide, an hsp70 polypeptide, and a cytotoxic polypeptide to trigger an immune response directed against cancer cells are provided. | 2010-11-18 |
20100292310 | MICRO-RNA SCAFFOLDS AND NON-NATURALLY OCCURRING MICRO-RNAS - The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196 | 2010-11-18 |
20100292311 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION - Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof. | 2010-11-18 |
20100292312 | ANTI-DLL4 ANTIBODIES AND METHODS USING SAME - The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies. | 2010-11-18 |
20100292313 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY - The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula II: | 2010-11-18 |
20100292314 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE - The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions. | 2010-11-18 |
20100292315 | METHOD FOR THE TREATMENT OF FOOD, FEED AND AGRICULTURAL PRODUCTS WITH A POLYENE ANTIFUNGAL COMPOUND - The present invention provides an aqueous antifungal composition comprising a polyene antifungal compound and a thickening agent. The composition can be used in the protection against the development of fungi on food, feed and agricultural products. | 2010-11-18 |
20100292316 | IMPROVED THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING CHROMAN RING COMPOUNDS - The instant invention concerns chroman ring derivative compounds such as vitamin E derivatives and methods for their use. In certain aspects, methods for treating subjects comprising Arg, JNK, p73, NOXA or FOXO1 positive cancers are provided. In still further aspects, methods for treating cell proliferative disease such as cancer by administration of a chroman ring compound in conjunction with a P13 or Akt kinase inhibitor are described. | 2010-11-18 |
20100292317 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS - The present invention relates to a method of treatment and/or prophylaxis of a microbial infection, comprising the step of administering an effective amount of a compound of formula (I), in which X and Y are either the same or different and selected from a heteroatom; is a double or single bond depending on the heteroatoms X and Y; R | 2010-11-18 |
20100292318 | ANTIBACTERIAL COMPOSITION COMPRISING SALVIA EXTRACTS - The present invention relates to a selectively purified tanshinone compounds containing extract from the root of a | 2010-11-18 |
20100292319 | PROCESS FOR PREPARING BENZOFURANS - There is provided a process for the preparation of a compound of formula (I), wherein R | 2010-11-18 |
20100292320 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS - The present disclosure provides a compound of general Formula (I) having enzyme inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2010-11-18 |
20100292321 | BIOFILM CONTROL - Compositions and methods suitable for killing bacteria and controlling biofilms comprising one or more microorganisms are provided wherein molecules capable of emulating cell-to-cell signal molecules of the microorganisms are utilized. | 2010-11-18 |
20100292322 | Bis-Platinum Complexes With Antitumor Activity - A compound of general formula (I): in which: R is selected from the group consisting of (C | 2010-11-18 |
20100292323 | Aqueous Microemulsions Containing Pyrethroid Compounds - The present invention relates to new aqueous microemulsions containing organic pesticide compounds of limited water-solubility and to their use for plant protection, including seed and crop protection, and protection or non-living material. The aqueous microemulsions comprise a) at least one pyrethroid compound P; b) at least one organic solvent, selected from compounds of the formula I R | 2010-11-18 |
20100292324 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof - The present invention relates to multi-substituted m-diarylanilines or pharmaceutically acceptable salts thereof, wherein X, R | 2010-11-18 |
20100292325 | P-MENTHAWE-3-CARBOXYLIC ACID ESTERS TO TREAT AIRWAYS DISEASES - The present invention relates to methods and devices for treating sensory discomfort in the upper airways of a human; treating sensory discomfort in the oropharynx of a human; alleviating pain from pharyngitis in a human; alleviating cough in a human; and ameliorating the symptoms and signs of asthma, dyspnea, sleep apnea, snoring or chronic obstructive pulmonary disease in a human. According to the invention, an active compound is delivered, preferably selectively delivered, to the oropharynx, preferably the oropharyngeal surfaces, more preferably the lower retropalatal oropharynx (LRO) of the patient. According to the invention, the active compound is a compound of the following formula, wherein R is C | 2010-11-18 |
20100292326 | PHARMACEUTICAL COMPOSITION COMPRISING S-NITROSOGLUTATHIONE AND POLYSACCHARIDE - The invention relates to pharmaceutical compositions comprising S-nitrosoglutathione and one or more polysaccharide-type polimer(s) together with one or more pharmaceutically accepted polymer(s) and additive(s). The invention is based on the discovery that polysaccharide-type polymers (such as chitosan) are capable of stabilizing the otherwise highly labile GSNO. | 2010-11-18 |
20100292327 | TREATMENT OF ASPIRIN RESISTANCE WITH BETAINE AND/OR BETAINE ENRICHED MOLASSES - Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof | 2010-11-18 |
20100292328 | Cosmetic Compositions Containing Esters of 2-ethylbutanol - The invention relates to the use of esters of 2-ethylbutanol with C | 2010-11-18 |
20100292329 | 4-HYDROXY BENZOATE DERIVATIVES FOR USE IN THE TREATMENT OF INFECTION, INFLAMMATION OR PAIN - A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R | 2010-11-18 |
20100292330 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION - The invention provides compositions comprising one or more long chain polyunsaturated fatty acids, nitric oxide releasing compounds, and medium chain triglycerides and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals. | 2010-11-18 |
20100292331 | Biomarkers for Prostate Cancer and Methods Using the Same - Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer. | 2010-11-18 |
20100292332 | RAPID-ACTING, BLOOD-ARGININE-LEVEL-INCREASABLE ORAL PREPARATION COMPRISING CITRULLINE AND ARGININE - The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect. | 2010-11-18 |
20100292333 | COMPOSITIONS SUITABLE FOR THE TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND NAILS - The present invention relates to pharmaceutical compositions suitable for the topical treatment of fungal infections of the skin and nails, such as tinea pedia and tinea cruris, among others. The active ingredients of the present compositions are low molecular weight organic acids and their salts, many of which are previously known as antifungal agents to some degree but which, when used in combination, produce a synergistic enhancement in antifungal potency such that the combined effect is greater than that when used by the agents alone. The antifungal activity of the active ingredients is further enhanced through the use of non-volatile hygroscopic solvents rather than the aqueous or volatile organic solvents used in the art. | 2010-11-18 |
20100292334 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their to pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2010-11-18 |
20100292335 | USE OF ORGANIC COMPOUNDS - The present invention provides methods for the prevention of, delay of progression to or the treatment of diseases modulated by an increase in tissue bradykinin levels by administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with (i)) an ACE inhibitor or a pharmaceutically acceptable salt thereof, (II) an angiotensin II receptor blocker, or a pharmaceutically acceptable salt of either. | 2010-11-18 |
20100292338 | SILK MEDICAL DEVICE WITH ANTIMICROBIAL PROPERTIES AND A METHOD OF MANUFACTURE THEREOF - A silk medical device is described, which is useful for the treatment of wounds to prevent infection. The silk medical device is manufactured from a silk protein material that is loaded with a polymeric cationic antimicrobial, such as polyhexamethylene biguanide (PHMB). | 2010-11-18 |
20100292339 | Genetic Polymorphisms Predictive of Nutritional Requirements for Choline in Subjects - Methods of predicting susceptibility of a subject to develop one or more choline deficiency-associated health effects are provided, comprising determining a genotype of the subject with respect to at least one choline metabolism gene and comparing the genotype of the subject with at least one reference genotype associated with susceptibility to develop the one or more choline deficiency-associated health effects. | 2010-11-18 |
20100292340 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 2010-11-18 |
20100292341 | QUICK DISSOLVE COMPOSITIONS OF MEMANTINE HYDROCHLORIDE - The present invention relates to quick dissolve pharmaceutical compositions. More particularly the invention relates to quick dissolve pharmaceutical compositions of memantine hydrochloride capable of dissolving in the oral cavity and process for preparing such compositions. The quick dissolve pharmaceutical compositions of memantine hydrochloride contain at least one water-soluble diluent in particular a mono- or disaccharide and at least one disintegrant and optionally other pharmaceutically acceptable excipients. | 2010-11-18 |
20100292342 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof - The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease. | 2010-11-18 |
20100292343 | USE OF A DIALKYLKETONE PEROXIDE AS BIOCIDAL, STERILIZING, ANTISEPTIC, DISINFECTING AND ANTI-PARASITIC AGENT - The invention presented here establishes the use of a dialkyl ketone peroxide as a sterilizing, antiseptic, disinfecting and anti-parasitic agent, with no apparent toxicity nor ecotoxicity, and a very wide spectrum of activity in terms of the type of organisms on which it acts (bacteria, virus, fungi, spores, mycobacteria, protozoa, algae, prions, arachnids, mites, insects, etc.), and in terms of the type of applications in which it can be employed (human and animal therapy, hygiene, packing, medical and industrial instruments, sanitary surfaces and healthcare environments, premises, surfaces in general, industrial installations, refrigeration towers, sanitary hot water systems, purification of drinking water for human or animal consumption, etc.). Likewise, the current invention illustrates the use of a composition comprising such dialkyl ketone peroxides. Finally, the invention presented here provides a method of sterilisation, disinfection, asepsia or deparasitisation that involves the application of said composition. | 2010-11-18 |
20100292344 | Methods and Compositions for Treating Thalamocortical Dysrhythmia - This invention relates to methods of inhibiting a Ca | 2010-11-18 |
20100292345 | THERAPEUTIC USES OF CANNABIGEROL - The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis. | 2010-11-18 |
20100292346 | Stereoisomers Propofol Therapeutic Compounds - A (−)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic. | 2010-11-18 |
20100292347 | Process to thicken aqueous compositions, notably with an acid ph, by means of organophosphate polymers, and the aqueous compositions obtained - A first object of the invention is a process for thickening of an aqueous composition, through the introduction into the said composition for thickening of at least one polymer, characterised in that the said polymer contains at least one anionic monomer, which is an organophosphate monomer. | 2010-11-18 |
20100292348 | DETECTION OF METHYLATED DNA AND DNA MUTATIONS - The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence. | 2010-11-18 |
20100292349 | PROCESS - A process for the preparation of at least one ARN acid or salt thereof comprising: (I) allowing at least one ARN acid salt to form during the production of crude oil in the presence of water; (II) removing at least 5 wt % of the formed at least one ARN acid salt, e.g. from the oil water interface; and optionally (III) converting said salt into an acid. | 2010-11-18 |
20100292350 | Processes For Hydromethanation Of A Carbonaceous Feedstock - The present invention relates to processes for preparing gaseous products, and in particular methane, via the catalytic hydromethanation of a carbonaceous feedstock in the presence of steam, syngas and an oxygen-rich gas stream. | 2010-11-18 |
20100292351 | PROCESS TO PREPARE CROSSLINKABLE TRIFLUOROSTYRENE POLYMERS AND MEMBRANES - Described herein is a process to prepare crosslinkable polymers based on trifluorostyrene, and their use as polymer electrolyte membranes. | 2010-11-18 |
20100292352 | PREPARATION AND APPLICATION OF CHAIN-EXTENDING CONCENTRATES FOR POLYESTER FOAMING PROCESS - The composition and the preparation of a chain-extending concentrate for production of foamed cellular materials of aromatic polyesters is disclosed in this invention. The chain-extending concentrate includes an ethylene-acrylate copolymer, a high-temperature thermoplastic and a multifunctional compound. The preparation process includes two steps: 1) Mixing and melt blending the multifunctional compound and the HT thermoplastic resin into the matrix of the ethylene-acrylate copolymer in an internal mixer and 2) extrusion of the mixture at a temperature below the melting point or reaction temperature of the multifunctional compound. | 2010-11-18 |
20100292353 | Silicone Antifoam Particles - Antifoam particles contain: (A) porous copolymers of urea or melamine or a mixture thereof with an alkanal, and (B) a silicone antifoam composition which is liquid at 0° C. The invention also provides pulverulent antifoam agents which comprise antifoam particles and optionally further carrier materials. | 2010-11-18 |
20100292354 | AQUEOUS BINDER COMPOSITION FOR MINERAL FIBERS - An aqueous binder composition for mineral fibres comprises a water-soluble binder component obtainable by reacting, in one or more steps, at least one alkanolamine, at least one carboxylic anhydride and at least one polyalkylene glycol component selected from polyalkylene glycols, copolymers and derivates thereof and, optionally, treating the reaction product with a base. | 2010-11-18 |
20100292355 | ALKENYL-AROMATIC FOAM HAVING GOOD SURFACE QUALITY, HIGH THERMAL INSULATING PROPERTIES AND LOW DENSITY - Prepare an alkenyl-aromatic foam having good surface quality, high thermal insulating properties and low density using an extrusion method by expanding a foamable polymer composition of an alkenyl-aromatic polymer composition containing less than 20 weight-percent covalently bonded halogens and having a polydispersity of less than 2.5 and a water solubility greater than 0.09 moles per kilogram and 2.2 moles per kilogram or less at 130 degrees Celsius and 101 kilopascals pressure and 0.8-2 moles per kilogram of a blowing agent containing 0.4 moles per kilogram or more of a chlorine-free fluorinated blowing agents and water at a concentration of at least 0.22 moles per kilogram; wherein moles per kilogram are relative to kilograms of alkenyl-aromatic polymer. The resulting foam has a density of 64 kilograms per cubic meter or less and a thermal conductivity of 32 milliwatts per meter-Kelvin or less after 180 days. | 2010-11-18 |
20100292356 | PREPARATION METHOD OF POLYBENZIMIDAZOLE - Disclosed is a method of preparing porous polybenzimidazole. The method includes providing polyaminoimide by reacting aromatic amine including at least two ortho-positioned amino groups and acid dianhydride, obtaining polypyrrolone from the polyaminoimide, subjecting the polypyrrolone to alkaline treatment, and subjecting the alkaline-treated polypyrrolone to heat treatment. The polybenzimidazole shows permeability and selectivity for various gases due to a fractional free volume and well-connected picopores. | 2010-11-18 |
20100292357 | PROCESS FOR PREPARING POLYDIMETHYLSILOXANES ON SULPHONIC ACID CATION EXCHANGE RESINS - The invention relates to a process for the targeted reorganization of polydimethylsiloxanes over sulphonic acid-containing cation exchange resins which have water contents of 8 to 25% by weight, and polydimethylsiloxanes thus prepared and the use thereof. | 2010-11-18 |
20100292358 | RESIN COMPOSITION FOR OPTICAL COMPONENTS AND OPTICAL COMPONENT USING THE SAME - The present invention relates to a resin composition for optical components, the resin composition being an ultraviolet-curable transparent resin composition to be used as a material for an optical component, in which the resin component includes the following component (A) as a main component and the following component (B) being a photo-cationic polymerization initiator: (A) an epoxy resin having two or more epoxy groups in one molecule thereof; and (B) an onium salt containing a hexafluorophosphate ion as an anion component. | 2010-11-18 |
20100292359 | Reaction-Curable Adhesive Composition and Dental Adhesive Kit - A reaction-curable adhesive composition exhibiting acidity is formed form a weakly acidic to alkaline composition (I) comprising (a) a polymerizable monomer and (b) a compound represented by the following formula (1) and a strongly acidic composition (II) comprising (a) a polymerizable monomer. | 2010-11-18 |
20100292360 | Pre-Treated Acid-Reactive Fillers and Their Use in Dental Applications - A dental filler and dental resin restorative composition containing the dental filler is provided. The dental filler is prepared by pre-treating an acid-reactive filler with a polymerizable monomer or oligomer pre-treatment chemical having at least one acid or acid-precursor functional group, at least one polymerizable unsaturated carbon-carbon bond, and a molecular weight of about 1,000 grams per mole or less. | 2010-11-18 |
20100292361 | HYDROSILYLATION REACTIONS ACTIVATED THROUGH RADIATION - η-cyclopentadienyl-tri(σ-hydrocarbyl) platinum compounds in which the cyclopentadienyl ring is linked to a hydrolysable silyl group by an alkylene group are effective light-activated hydrosilylation catalysts which are also non-volatile. | 2010-11-18 |
20100292362 | Dental Composition Containing a Surfactant and an F-Containing Compound, Process of Production and Use Thereof - The invention relates to a curable dental composition comprising a) a curable organopolysiloxane polymer, b) a crosslinker compound capable of crosslinking said organopolysiloxane polymer, c) a catalyst capable of catalyzing a crosslinking reaction of component (A) and component (B), d) a surfactant, e) a F-containing compound, wherein the F-containing compound has the following formula: (G1-L1-O)s-Rfa-O-L2-G2 wherein: G1 and G2 each independently represents a non-ionic endgroup that is free of polyoxyalkylene groups or contains polyoxyalkylene such that the total amount thereof in the F-containing compound is not more than 10% by weight based on the molecular weight of the F-containing compound; L1 and L2 each independently represents an aliphatic hydrocarbon group or a partially or fully fluorinated aliphatic hydrocarbon group; Rfa represents a mono-valent or divalent partially or fully fluorinated aliphatic group or a partially or fully fluorinated aliphatic group interrupted by one or more oxygen atoms; with the proviso that at least one of the following conditions is fulfilled: (i) at least one of the moieties L1-G1 and L2-G2 is partially or fully fluorinated or (ii) Rf is a partially or fully fluorinated aliphatic group interrupted by one or more oxygen atoms. The invention also relates to a kit of parts and a method of producing a dental composition as well as the use of the dental composition for the preparation of or as impression material or for the preparation of crowns and bridges. | 2010-11-18 |
20100292363 | MATERIAL FOR BUILDING UP STUMPS - The invention relates to a polymerizable material for the production of a dental material for building up stumps, having the following characteristics: —the material comprises at least one polymerizable monomer, oligomer, and/or pre-polymer, —the total filler content of the material is 50 to 85% by weight, —the material comprises 5 to 25% by weight nano-filler, having a mean particle size d5o of 300 nm or less, wherein at least 50% by weight of said nano-filler has a particle size of 200 nm or less, —the material comprises 35 to 75% by weight micro-filler, having a mean particle size d | 2010-11-18 |
20100292364 | Filler material for crowns, crown material containing same, and method of manufacturing thereof - The present invention provides a composition for crown material including resin and a fine spherized composite glass powder. The fine composite glass powder of the present invention for such a configuration has superior qualities with regard to both sintering and optical characteristics, and can be used as a filler for crown material. | 2010-11-18 |
20100292365 | Latex Compositions Comprising Pozzolan and/or Cement Kiln Dust and Methods of Use - The present invention includes methods and compositions that include a latex, and at least one of a natural pozzolan or cement kiln dust. An embodiment includes a method comprising: placing a latex composition in a subterranean formation, wherein the latex composition comprises: latex, a component selected from the group consisting of a natural pozzolan, cement kiln dust, and a combination thereof, and water; and allowing the latex composition to set. Another embodiment of the present invention includes a latex composition comprising: latex, a component selected from the group consisting of a natural pozzolan, cement kiln dust, and a combination thereof. | 2010-11-18 |
20100292366 | Vulcanizable rubber mixture and rubber products comprising the same - The vulcanizable rubber mixture according to this invention is used for rubber products in particular vehicle tires and vehicle tire treads, but also technical rubber products like belts on conveyor systems, technical hoses, vibration dampers and impact dampers, or wire coatings. All these products benefit from the improved processability that is achieved with the invention in that the mixture comprises a polymer represented by the formula F1-A-F2, or a mixture of F1-A-F2 with an astral or radial coupling product of F1-A-units, coupled by a multivalent coupling agent; wherein F1 represents a terminal functionalization of the polymeric chain, F2 represents a terminal functionalization different from F1; and A represents the polymeric chain of a polymer formed by the copolymerization between one or more conjugated dienes with one or more aromatic vinyl monomers. | 2010-11-18 |
20100292367 | POLYESTER COMPOSITIONS FOR LONG-TERM OUTDOOR EXPOSURE - The present invention relates to the field of ultraviolet light stabilized polyester compositions, particularly it relates to ultraviolet light stabilized polyester compositions for manufacturing articles having good mechanical properties and a good surface appearance upon long-term outdoor exposure and/or heat exposure. | 2010-11-18 |
20100292368 | ACRYLIC-RESIN-CONTAINING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME - Object of the present invention is to provide an acrylic-resin-containing film which exhibits high transparency, high heat resistance, and markedly improved brittleness, a polarizing plate using the acrylic-resin-containing film which improves a yield of operation such as punching of a polarizing plate or bonding panels and a liquid crystal display device which can keep to exhibit excellent visibility in long-terms usage in harsh environment. These objects have been achieved by the acrylic-resin-containing film comprising a acrylic resin (A) and a cellulose ester resin (B), or comprising the acrylic resin (A), the cellulose ester resin (B) and at least a resin (D) which is other than the resins (A) and (B) and has a glass transition temperature Tg of 120-300° C. The film is characterized in that it has a haze of less than 2%, a tensile softening point of 120-150° C. and undergoes no ductile fracture. | 2010-11-18 |
20100292369 | BITUMEN MIXTURE AND USE THEREOF - Bitumen mixtures for high-quality overlayment roofing membranes have to meet particularly high requirements. Such bitumen mixtures are typically produced from polymer-modified bitumen having an SBS rubber content of at least 10% by weight and may also have just a comparatively low filler content. | 2010-11-18 |
20100292370 | Rubber Compositions - The present invention relates to a rubber composition containing a filler comprising at least one rubber containing olefinic unsaturation and functionalized nano transition metal oxide and/or sulfide particles. The invention further relates to a method of manufacture the rubber compositions and to the use of such compositions in tyres, belts and/or hoses. | 2010-11-18 |
20100292371 | POLYPROPYLENE RESIN COMPOSITION AND MOLDED ARTICLE - Provided are a polypropylene resin composition which produces only a little mold staining at the time of molding, which is excellent in the stability against light and the molding processability, which has good balance between high rigidity and impact resistance, and which can give a molded article excellent in flow mark appearance and weld appearance when being processed into a molded article, and a molded article produced therefrom. The polypropylene resin composition of the present invention contains 99 to 60 parts by weight of propylene-based polymer (A), 1 to 40 parts by weight of inorganic filler (B) having an average particle diameter of 0.01 to 100 μm, and 0.05 to 5 parts by weight, per 100 parts by weight of the resin composition (I), of an hindered amine-type light stabilizer (C) which satisfies the specified requirements (a), (b) and (c), provided that the combined amount of the propylene-based polymer (A) and the inorganic filler (B) is 100 parts by weight. | 2010-11-18 |
20100292372 | NON-IONIC SURFACTANT ADDITIVES FOR IMPROVED PARTICLE STABILITY IN HIGH ORGANIC INKJET INKS - Inkjet ink compositions and methods for increasing inkjet ink particle stability are disclosed herein. In an embodiment, a latex polymer-containing inkjet ink composition comprises a secondary alcohol ethoxylate and a fluoro-surfactant at a concentration ratio effective to increase particle stability of the inkjet ink composition when the pigment particles are substantially electrostatically dispersed. In another embodiment, an inkjet ink composition comprises a latex dispersion having a conductivity of no more than about 1.5 mS/cm. | 2010-11-18 |
20100292373 | ADDUCTS OF LEVULINIC DERIVATIVES WITH EPOXIDIZED FATTY ACID ESTERS AND USES THEREOF - The present disclosure relates to methods of preparation of compounds resulting from the reaction of levulinic esters and epoxidized unsaturated fatty acid esters. The compounds are useful as renewable biomass-based plasticizers for a variety of polymers. Mono-, di- and tri-ketal adducts formed in a reaction between alkyl esters of levulinate and epoxidized unsaturated fatty acid esters derived from vegetable oils are also disclosed. | 2010-11-18 |
20100292374 | CROSSLINKED POLYMERS AND METHODS OF MAKING THE SAME - Methods are described that include elongating, e.g., by stretching and/or compressing, a polymeric material, such as an ultra-high molecular weight polyolefin (e.g., an ultra-high molecular weight polyethylene (UHMWPE)), below, or above a melt temperature of the polymeric material to disentangle polymeric chains of the polymeric material. The disentangled materials provided can be effectively and efficiently crosslinked, e.g., by using ionizing radiation (e.g., generated by a gamma radiation source and/or an electron beam source). Parts formed from the crosslinked polymeric materials have, e.g., high wear resistance, enhanced stiffness, as reflected in flexural and tensile moduli, a high level of fatigue and crack propagation resistance, and enhanced creep resistance. Some of the crosslinked polymeric materials have a low coefficient of friction. Prior to elongating, it can be desirable to slightly crosslink the polymeric material to impart shape memory into the polymeric material. | 2010-11-18 |
20100292375 | Biaxially stretched polymer film comprising a decarboxylation catalyst, its use in electrical insulation applications, and process for its production - Biaxially stretched film with polymeric constituents formed mainly of polyester in which the film includes at least one copper salt and one halide, with the resulting film having an AC (alternating current) dielectric strength of at least 100 kV/mm at 23° C. and 50 Hz. The invention further relates to the use of the film of the invention, in particular in solar modules, and also to a process for its production. | 2010-11-18 |
20100292376 | PHOSPHORUS-CONTAINING FLAME RETARDANTS - A flame-retardant resin composition comprises a base resin (A), such as a polyester, polyamide or polycarbonate resin, and an organophosphorus compound (B) having at least one of the following formulas (I), (II) and (III): | 2010-11-18 |
20100292377 | AQUEOUS MIXTURES CURABLE PHYSICALLY, THERMALLY OR BOTH THERMALLY AND WITH ACTINIC RADIATION, PROCESSES FOR PREPARING THEM, AND USE THEREOF - Disclosed herein is an aqueous mixture curable physically, thermally or both thermally and with actinic radiation, comprising (A) at least one polyurethane binder, which is ionically stabilized, nonionically stabilized, or a combination thereof, and which is saturated, unsaturated, grafted with olefinically unsaturated compounds, or a combination thereof; (B) at least one pigment, which is a color pigment, effect pigment, or a combination thereof; and (C) at least one phosphoric ester of the general formula (R | 2010-11-18 |
20100292378 | TRANSPARENT COMPOSITE MATERIAL - This invention relates to: (1) a transparent composite material comprising a cured product of a resin composition having from 60 to 90% by mass of a vinyl ester resin composition which has a vinyl ester resin being synthesized from an aliphatic epoxy compound and from 10 to 40% by mass of synthetic smectite that is organized with a quaternary ammonium salt and/or a quaternary phosphonium salt and has a number average particle diameter of from 10 to 300 nm and an aspect ratio of from 10 to 300, the composition being cured, (2) a method for producing the transparent composite material, wherein the raw material composition for the composite material before curing is cured with an electron beam (EB), an ultraviolet ray (UV) or heat, and (3) a display device and a substrate for a solar cell comprising the transparent composite material as a substrate. | 2010-11-18 |
20100292379 | PVC resin composition and products made of the same - A PVC resin composition having high flame retardancy and low smoke generation comprises a formula including a PVC resin, inorganic powders, a additive, a toughening agent, a coupling agent and an initiator mixed by proportion, wherein the initiator cooperates with the coupling agent to improve a binding effect of the inorganic powders inside the PVC resin composition to endow a PVC product if made of the composition to provide with excellent tensile strength and elongation and enable the product to perform high flame retardancy and low smoke generation during combustion. | 2010-11-18 |
20100292380 | POLYMERIC DEFOAMER ADDITIVE - The present invention relates to a cost-effective and environmentally friendly polymeric defoamer formulation for use in various industrial applications that does not contain oil, EBS or free silicone. | 2010-11-18 |
20100292381 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED BODY OBTAINED BY MOLDING THE SAME - Disclosed is a thermoplastic resin composition obtained by mixing together 100 parts by mass of a polylactic acid resin or a polylactic acid resin composition, 0.01 to 10 parts by mass of a peroxide and 0.01 to 5 parts by mass of a silane compound having two or more functional groups selected from an alkoxy group, an acrylic group, a methacrylic group and a vinyl group. The polylactic acid resin composition may include 90 to 99.5% by mass of the polylactic acid resin and 0.5 to 10% by mass of a plasticizer. The thermoplastic resin composition may further include a fibrous reinforcing material and a polycarbodiimide compound, and where necessary, a flame retardant. | 2010-11-18 |
20100292382 | Aluminum Phosphate, Polyphosphate, and Metaphosphate Particles and Their Use as Pigments in Paints and Method of Making Same - An aluminum phosphate composition comprising aluminum phosphate, aluminum polyphosphate, aluminum metaphosphate, or a mixture thereof. The composition may be characterized by, when in powder form, having particles wherein some of the particles have at least one or more voids per particle. In addition, the composition is characterized by exhibiting two endothermic peaks in Differential Scanning Calorimetry between about 90 degrees to about 250 degrees Celsius. The composition is also characterized by, when in powder form, having a dispersibility of at least 0.025 grams per 1.0 gram of water. The composition is made by a process comprising contacting phosphoric acid with aluminum sulfate and an alkaline solution to produce an aluminum phosphate based product; and optionally calcining the aluminum phosphate, polyphosphate or metaphosphate based product at an elevated temperature. The composition is useful in paints and as a substitute for titanium dioxide. | 2010-11-18 |
20100292383 | ELASTOMER COMPOSITION WITH RECLAIMED FILLER MATERIALS - The present invention is directed to a carrier elastomer composition having an elastomer material between about 20% to about 80% by weight of the carrier elastomeric composition. The carrier elastomeric composition also includes a fine agglomerates mixture of filler derived from pyrolyzed polymeric materials. The fine agglomerates mixture of filler comprises between about 10% to about 70% by weight of the carrier elastomeric composition. The carrier elastomeric composition also has a processing oil that is present in a quantity of about 25% to about 30% by weight of the carrier elastomeric composition. The carrier elastomeric composition in accordance with the present invention serves as a carrier for transporting the fine agglomerates mixture which includes agglomerate having an average particle size equal to or less than 35 nm. | 2010-11-18 |
20100292384 | URETHANE ADHESIVE COMPOSITION - A urethane adhesive composition includes a first liquid and a second liquid, the first liquid containing a prepolymer obtained by reacting a polyisocyanate and a high-molecular-weight polyol (I), and at least one filler selected from talc and calcium carbonate, and containing 20 parts by mass or more of talc, 0 to 40 parts by mass of calcium carbonate, and 10 parts by mass or more of zeolite based on 100 parts by mass of the polyisocyanate, the high-molecular-weight polyol (I), and the prepolymer in total, the second liquid containing a high-molecular-weight polyol (II) and a low-molecular-weight polyol, the ratio of the number of moles of hydroxyl groups derived from the low-molecular-weight polyol to the total number of moles of hydroxyl groups derived from the high-molecular-weight polyol (I) and the high-molecular-weight polyol (II) being four or more. | 2010-11-18 |
20100292385 | PROCESS FOR THE PRODUCTION OF MOLDINGS WITH REDUCED FORMATION OF DEPOSIT - The invention relates to processes for the production of moldings via shaping of thermoplastic molding compositions F with reduced formation of deposit on the shaping mold, and it is essential to the invention that the thermoplastic molding compositions F comprise an amount of from 0 mg/kg to 100 mg/kg (calculated as the total of the mg of Mg and the mg of Ca per kg of thermoplastic molding composition F and determined by means of atomic emission spectrometry using inductively coupled plasma (ICPAES)) of magnesium compounds and/or calcium compounds; the invention further relates to the use of molding compositions F in the inventive processes, and also to moldings which can be produced by the inventive processes. | 2010-11-18 |